Altimmune (ALT) Net Margin (2010 - 2025)
Altimmune (ALT) posted quarterly Net Margin of 291750.0% for Q4 2025, up 75535000.0% year-over-year from N/an in Q4 2024, and up 176.72% quarter-over-quarter from 380280.0% in Q3 2025.
Powered by 
Analysis
Altimmune (ALT) Net Margin (2010 - 2025) Analysis & Trends
Altimmune (ALT) has reported Net Margin for 16 consecutive years, with 291750.0% the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Margin rose 75535000.0% year-over-year to 291750.0%; the TTM figure through Dec 2025 stood at 36878.05% (up 51217305.0% YoY), while the FY2025 annual figure was 36878.05%, up 41236305.0% from the prior year.
- Net Margin grew to 291750.0% in Q4 2025 per ALT's latest filing, from 380280.0% in the prior quarter.
- Across five years, Net Margin topped out at 291750.0% in Q4 2025 and bottomed at 1175800.0% in Q3 2022.
- Historically, Net Margin has averaged 243006.47% across 5 years, with a median of 173898.81% in 2022.
- Annual changes were most pronounced in 2022 — Net Margin slumped 115459114 bps — and 2023, when it soared 117008978 bps.
- Altimmune's Net Margin stood at 164.24% in 2021, then slumped by 22485 bps to 37092.31% in 2022, then tumbled by 131 bps to 85516.22% in 2023, then tumbled by 442 bps to 463600.0% in 2024, then jumped by 163 bps to 291750.0% in 2025.
- Business Quant data shows ALT's Net Margin at 291750.0% in Q4 2025, 380280.0% in Q3 2025, and 442920.0% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -3.12% |
| 10 | Altimmune | 624.02 Mn | 624.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -36,126.92% |
| Sep 30, 2025 | -380,280.00% |
| Jun 30, 2025 | -442,920.00% |
| Mar 31, 2025 | -391,500.00% |
| Dec 31, 2024 | -463,600.00% |
| Sep 30, 2024 | -456,900.00% |
| Jun 30, 2024 | -492,800.00% |
| Mar 31, 2024 | -487,880.00% |
| Dec 31, 2023 | -85,516.22% |
| Sep 30, 2023 | -5,710.22% |
| Jun 30, 2023 | -269,566.67% |
| Mar 31, 2023 | -95,680.95% |
| Dec 31, 2022 | -83,307.69% |
| Sep 30, 2022 | -1,175,650.00% |
| Jun 30, 2022 | -251,650.00% |
| Mar 31, 2022 | -61,062.50% |
| Dec 31, 2021 | -728.99% |
| Sep 30, 2021 | -21,208.86% |
| Jun 30, 2021 | -18,121.68% |
| Mar 31, 2021 | -1,773.76% |